Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of solifenacin suspension in pediatric overactive bladder
2011-002066-20Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Solifenacin succinate suspension with Placebo suspension (2 arms). Primary endpoint: Change from baseline in mean volume voided per micturition. Started Jan 2012; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2011-002066-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002066-20.